Medicus Pharma has partnered with Swanielle to expand its Phase II trial for treating basal cell carcinoma into the Asia-Pacific region.

Sudo Biosciences has begun a Phase I trial of SUDO-550, a drug candidate designed to treat neuroinflammatory diseases.

Pneumonia epidemic peaks historically occur every four to seven years, with the last epidemic of pneumonia in the UK occurring in 2019-20.

The company will evaluate the Hepzato kit in combination with the standard of care in liver-dominant metastatic colorectal cancer patents.

GLP-1R injectable drugs are effective in treating obesity, but their success points to a gap in the market: oral alternatives ...

Minghui has reported positive topline outcomes from the Phase III trial of MH004 for treating mild to moderate atopic ...

Novocure’s TTFields therapy combined with chemo improved overall survival by 16.2 months compared to 14.16 months with chemo ...

Cantargia has commenced an expanded segment of the ongoing Phase I trial of its antibody, CAN10, with the first participant ...

Qatar Foundation member Sidra Medicine has conducted the industry-sponsored ‘sunRIZE’ trial for paediatric congenital ...

The results demonstrate the safety and efficacy of Fasenra in the treatment of acute eosinophilic exacerbations in asthma and ...

Gilead Sciences has announced the outcomes from the Phase III PURPOSE 2 trial evaluating lenacapavir for HIV prevention.

UroGen Pharma has reported the outcomes from a long-term follow-up study of JELMYTO for pyelocalyceal solution for treating ...